Neuphoria Therapeutics, Inc. (NEUP) - Long-Term Liabilities to Capital
The development of clinical trials requires a steady influx of funds, yet the current reserves of Neuphoria Therapeutics Inc. (NEUP) remain sufficient. The long-term debt-to-equity ratio demonstrates a debt profile where 0.00 represents the latest metric reading. Management is aggressively promoting anxiety medications, seeking strategic partnerships. The creation of small molecules for psychiatric disorders will ensure high inertia for repeat drug sales.
&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_NEUP_-_Neuphoria-Therapeutics-Inc._-_Long-Term-Debt-to-Equity-Ratio "NEUP - Neuphoria Long-Term Debt to Capital over the range 12/25/2024 - 11/01/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Neuphoria Therapeutics Inc.
- current price and projected stock value:
- market capitalization indicators:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Debt to Capital Neuphoria Therapeutics Inc.|NEUP - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Neuphoria|NEUP - Company Aggregate Debts|Debts to Book Value Neuphoria Therapeutics Inc.|NEUP - Company Long-Term Liabilities|Company Short-Term Debts Neuphoria Therapeutics|Critical Liquidity Ratio bionomics.com.au
- net income and valuation ratios data:
Summary company analysis:NEUP (bionomics.com.au)
Implementing laboratory robotics for molecule screening requires significant capital expenditures in automation. This ratio correlates liabilities with a maturity of over one year to the company's equity. An increase in this metric signals rising leverage to fund R&D. It is critical for investors to assess the balance between borrowed capital and financial stability. By analyzing the long-term debt-to-equity chart, one can determine the degree of debt load for Neuphoria Therapeutics Inc. (NEUP).
Competing companies
Long-Term Debt to Capital Ratio BIIB (Biogen Inc)|Long-Term Debt to Capital NBIX|RGC - Long-Term Liabilities to Capital|Axsome Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital acadia-pharm.com ACAD|XENE - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Catalyst Corp (CPRX)|Long-Term Debt to Equity Denali Therapeutics|Long-Term Debt to Capital Ratio HRMY (harmonybiosciences.com)|Long-Term Debt to Capital BHVN|AMLX - Long-Term Liabilities to Capital|Trevi Pharma - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Praxis Corp PRAX|AVXL - Long-Term Debt to Equity|Long-Term Liabilities to Equity CBLL|PRTA: Long-Term Debt to Capital|Alector - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Annexon Inc.|Long-Term Liabilities to Capital Omeros Corp. OMER|Long-Term Debt to Equity Neurogene Inc. (NGNE)|ACIU (acimmune.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital VYGR (Voyager Therapeutics, Inc.)|Ratio of Long-Term Indebtedness to Capital Neumora (NMRA)|Scilex Holding Co. - Long-Term Debt to Capital|TVGN - Long-Term Debt to Capital|ACOG (alphacognition.com) - Long-Term Debt to Equity Ratio|cogrx.com - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio IKT|SAVA (Cassava Sciences Inc) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital ASRT|COYA (coyatherapeutics.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Long-Term Liabilities to Capital|ABOS - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CRVO (CervoMed, Inc.)|ATHE: Long-Term Debt to Capital|Clene (CLNN) - Long-Term Debt to Capital|Long-Term Debt to Equity PepGen Inc|jupiterneurosciences.com - Long-Term Liabilities to Equity|Long-Term Debt to Capital RLMD|ANVS - Long-Term Liabilities to Capital|Grace Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Firefly Neuro AIFF|KLTO: Long-Term Debt to Equity Ratio|NeuroSense Therapeutics - Long-Term Loans to Capital Ratio|RVPH: Long-Term Debt to Capital|MTVA - Ratio of Long-Term Indebtedness to Capital|NRXS (NeurAxis, Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Helius Medical Technologies Inc. (HSDT)|Long-Term Debt to Equity Passage Bio, Inc. (PASG)|Ratio of Long-Term Indebtedness to Capital minervaneurosciences.com|Athira Pharma - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ADXN|Alzamend - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Cyclerion Therapeutics CYCN|protagenic.com (PTIX) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio KTTA|CRGT (Cortigent Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Avenue Therapeutics Inc. (ATXI)|Long-Term Debt to Equity Ratio BCLI (Brainstorm Cell Therapeutics, Inc.)|Ratio of Long-Term Indebtedness to Capital Cara Therapeutics Inc|Long-Term Debt to Equity Chromocell Therapeutics CHRO|ELYM: Long-Term Debt to Capital Ratio|Intra-Cellular - Long-Term Debt to Capital|Long-Term Liabilities to Capital Longboard Pharmaceuticals Inc|MRNS (Marinus) - Long-Term Debt to Equity Ratio|NKGen Biotech Corp (NKGN) - Long-Term Debt to Capital|Long-Term Debt to Equity NeuroBo Pharmaceuticals|sagerx.com - Long-Term Liabilities to Equity|Long-Term Debt to Equity Synaptogenix (SNPX)|Trevena Inc. - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital VIGL (Vigil Neuroscience, Inc.)|Anew Medical Inc. (WENA) - Long-Term Liabilities to Capital|CERE: Long-Term Debt to Equity Ratio